Acerta Pharma

August 13, 2019

Novartis cast-off gives Pharming a gap-filler

Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?

The cash register rings for Biontech and ADC Therapeutics

August 30, 2018

Seeking alpha in PI3K inhibition

Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.

August 01, 2017

Redx’s strange insolvency triggers Imbruvica follow-on buzz

January 30, 2017

Autoimmune disease vies with cancer to dominate the class of 2017

December 06, 2016

Ash – Early data for next generation of Imbruvica’s challengers

September 02, 2016

Snippet roundup: Tecentriq gets lung cancer win, Enbrel biosimilar patent dance intensifies

August 04, 2016

Big pharma’s R&D zero-to-hero story

July 14, 2016

Biotech venture funding falls from 2015 peak

June 27, 2016

As Brexit hits forex, spare a thought for those uncompleted deals

February 05, 2016

Pancreatic cancer 2016: this time it’s (getting) personal

Load More